ZIOPHARM, Inc. Initiates ZIO-101 Phase I/II Myeloma Study; Company Meets Milestone For Treatment Of First Patient

NEW YORK--(BUSINESS WIRE)--Jan. 31, 2006--ZIOPHARM Oncology, Inc. (OTC BB: ZIOP), announced today that ZIO-101, a novel and proprietary form of organic arsenic, has been administered to the first patient in a phase I/II trial in advanced myeloma. Interim data from an ongoing phase I trial suggest ZIO-101 can be given at significantly higher doses, with no significant toxicity, compared to arsenic trioxide, an inorganic arsenic currently approved to treat APL (acute promyelogenous leukemia). Arsenic trioxide has also shown activity in myeloma. The ongoing phase I study is currently in cohort five with dosing about 45 times higher than the approved dose of arsenic trioxide.

MORE ON THIS TOPIC